Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
argenx SE - American Depositary Shares
(NQ:
ARGX
)
546.83
-22.29 (-3.92%)
Streaming Delayed Price
Updated: 1:17 PM EDT, May 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about argenx SE - American Depositary Shares
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Analyst Ratings for argenx
April 21, 2023
Via
Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
April 18, 2023
From
argenx SE
Via
GlobeNewswire
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
April 17, 2023
From
argenx SE
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
April 12, 2023
Via
Benzinga
A Bearish Sign Appears On argenx's Chart
March 23, 2023
Via
Benzinga
Analyst Ratings for argenx
March 20, 2023
Via
Benzinga
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
March 20, 2023
Via
Benzinga
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
March 17, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
March 15, 2023
From
argenx SE
Via
GlobeNewswire
5 Analysts Have This to Say About argenx
March 03, 2023
Via
Benzinga
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
March 02, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces Planned Transition of Chief Operating Officer
March 02, 2023
From
argenx SE
Via
GlobeNewswire
Earnings Outlook For argenx
March 01, 2023
Via
Benzinga
Analyst Ratings for argenx
January 10, 2023
Via
Benzinga
Analyst Ratings for argenx
December 07, 2022
Via
Benzinga
Expert Ratings for argenx
December 07, 2022
Via
Benzinga
argenx Appoints Steve Krognes to Board of Directors
February 27, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
February 27, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
February 23, 2023
From
argenx SE
Via
GlobeNewswire
Immunovant Could Potentially Be An M&A Target, Writes Analyst
February 15, 2023
Via
Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
January 27, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
January 16, 2023
From
argenx SE
Via
GlobeNewswire
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
January 10, 2023
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in...
Via
Benzinga
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
January 09, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
argenx SE
Via
GlobeNewswire
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
December 22, 2022
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading.
Via
Benzinga
argenx Appoints Ana Cespedes to Board of Directors
December 12, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
December 10, 2022
From
argenx SE
Via
GlobeNewswire
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.